Treatment of chronic hepatitis C with PegIFN-alfa2b and ribavirin within a large German multicentric observational study: predictors of nonresponse in genotype 1 patients
D Hüppe, E Zehnter, S Mauss, MP Manns, G Teuber, D Tarek, S Kaiser, U Meyer, T Witthöft, B Möller, N Dikopoulos, J Brack, M Bilzer, G Tossing, M McGlaun · Zeitschrift für Gastroenterologie · 2009 · Heft 01
Bibliografische Angaben
Zusammenfassung
Aims: The current treatment of choice is a combination of pegylated interferon-alfa (PegIFN-alfa) plus ribavirin. Prediction of IFN efficacy before treatment has been mainly based on viral characteristics such as viral load and genotype. We therefore analyzed data from a large multicentric German surveillance study in order to identify additional host- related predictors of nonresponse. Methods: Between 9/2003 and 8/2008, 279 active sites treated a total of 4039 patients with weight-based PegIFN-alfa2b and ribavirin. As this is an ongoing surveillance trial, we have performed an interim analysis of formerly untr…
